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Autosomal-Recessive Osteopetrosis (ARO) comprises a heterogeneous group of bone diseases for which mutations in ﬁve genes are
known as causative. Most ARO are classiﬁed as osteoclast-rich, but recently a subset of osteoclast-poor ARO has been recognized as
due to a defect in TNFSF11 (also called RANKL or TRANCE, coding for the RANKL protein), a master gene driving osteoclast differenti-
ation along the RANKL-RANK axis. RANKL and RANK (coded for by the TNFRSF11A gene) also play a role in the immune system, which
raises the possibility that defects in this pathway might cause osteopetrosis with immunodeﬁciency. From a large series of ARO patients
we selected a Turkish consanguineous family with two siblings affected by ARO and hypogammaglobulinemia with no defects in known
osteopetrosis genes. Sequencing of genes involved in the RANKL downstream pathway identiﬁed a homozygous mutation in the
TNFRSF11A gene in both siblings. Their monocytes failed to differentiate in vitro into osteoclasts upon exposure to M-CSF and RANKL,
in keeping with an osteoclast-intrinsic defect. Immunological analysis showed that their hypogammaglobulinemia was associated with
impairment in immunoglobulin-secreting B cells. Investigation of other patients revealed a defect in both TNFRSF11A alleles in six
additional, unrelated families. Our results indicate that TNFRSF11A mutations can cause a clinical condition in which severe ARO is
associated with an immunoglobulin-production defect.Introduction
Autosomal-recessive osteopetrosis (ARO) in humans repre-
sents a heterogeneous group of diseases, including osteo-
clast-rich and osteoclast-poor forms.1 The osteoclast-rich
form, characterized by a normal or even elevated number
of nonfunctional multinucleated osteoclasts, is due to
defects in genes involved in the bone-resorbing function
of osteoclasts.2–5 The osteoclast-poor form, in which no
mature osteoclasts are present, has remained poorly under-
stood until recently, when our group identiﬁed TNFSF11
(MIM 602642) mutations in some patients (3% in our
cohort).6 A very rare form of osteopetrosis with anhydrotic
ectodermal dysplasia and immunodeﬁciency (MIM
300291), due to mutation of the IKBKG gene (NEMO,
[MIM 300248]), has also been reported.7
RANKL, the protein coded for by the TNFSF11 gene,
binds to two different receptors: the membrane-anchored
receptor RANK, coded by the TNFRSF11A gene (MIM
603499), and the soluble decoy receptor osteoprotegerin
(OPG), coded by the TNFRSF11B gene (MIM 602643).
RANKL signaling through RANK is fundamental for osteo-64 The American Journal of Human Genetics 83, 64–76, July 2008clast maturation, as demonstrated by osteopetrosis in mice
due to targeted deletion of either gene. In fact, Tnfrsf11a/
(rank knockout)8 and Tnfsf11/ (rankl knockout)9–11 mice
share a similar phenotype, with severe osteopetrosis due to
complete lack of mature osteoclasts, immune deﬁciency
with absent lymph nodes, defective mammary-gland mat-
uration, and other minor abnormalities. Monocytes from
both Tnfsf11/mice and ARO patients bearing mutations
in TNFSF11 differentiate normally when exposed to re-
combinant RANKL, conﬁrming that the defect is outside
the osteoclast lineage.6,9 By contrast, the osteoclast differ-
entiation defect of Tnfrsf11a/ mice cannot be rescued
by exogenous RANKL.8
Therefore, we analyzed genes involved in osteoclast dif-
ferentiation along the RANKL-RANK axis in other osteo-
clast-poor individuals without TNFSF11 mutations. Here,
we report seven mutations in the TNFRSF11A gene leading
to an osteoclast-poor ARO phenotype due to a cell-auton-
omous defect in eight patients. Importantly, as opposed
to TNFSF11 deﬁciency, osteopetrosis in TNFRSF11A-deﬁ-
cient patients could be rescued by hematopoietic stem
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demonstrate that even among patients with a similar phe-
notype (e.g., osteoclast-poor ARO), careful genetic diagno-
sis has signiﬁcant prognostic and therapeutic implications.
Material and Methods
Analysis of In Vitro Osteoclast Function
Human osteoclasts were generated by culture of peripheral blood
monocytes with M-CSF and RANKL as previously described,12
with minor modiﬁcations. PBMCs were isolated from 10 ml of
peripheral blood from the patients or an unrelated control and
cultured in a-MEM with 20 ng/ml M-CSF (R&D Systems) for
7 days, with a complete change of medium after 4 days. The M-
CSF-dependent macrophages were rinsed in PBS and then scraped
into freshmedium after incubation for 15min in 1mg/ml trypsin.
After cells were centrifuged and resuspended in fresh medium,
they were seeded on to 9 mm glass coverslips in 48-well plates
or 5 mm discs of dentine in 96-well plates (6 3 104 and 2 3 104
cells/well, respectively) and incubated with 20 ng/ml M-CSF and
100 ng/ml RANKL (Peprotech) for 10 days, with complete media
changes after 3 and 6 days. Cells were then ﬁxed in either parafor-
maldehyde (for light-microscopic analysis) or in glutaraldehyde
(for electron-microscopic analysis) as described previously.6 For
light microscopy, osteoclasts were immunostained for the vitro-
nectin receptor (VNR; antibody courtesy of Mike Horton, Univer-
sity College London), and acidic vesicles, F-actin, nuclei and the
dentine surface were visualized as previously described.6 Cells
were analyzed by the use of confocal microscopy with a Zeiss
LSM 510 confocal microscope equipped with argon (excitation
488 nm) and helium-neon (543 nm and 633 nm) lasers. Osteoclast
formation was quantiﬁed in cultures from patient 1A (Pt. 1A), Pt 6,
Pt 7, and appropriate controls by a count of the number of VNR-
positive cells with more than two nuclei (replicates of at least
four). For scanning electron microscopy, osteoclast cultures were
processed as previously described6 and then examined in a Jeol
35S scanning electron microscope at 10 kV. Images were taken
with SemAfore software.
Bone Biopsies
Bone biopsies were taken from the iliac crest. Tissue was ﬁxed in
formalin, demineralized in EDTA, and embedded in parafﬁn
according to standard procedures. Sections were stained with
hematoxylin and eosin or with toluidine blue. In one case (Pt.
5), sections were also stained for expression of tartrate-resistant
acid phosphatase (TRAcP), with napthol-ASBI-phosphate used as
substrate and pararosanilin used as coupler, and counterstained
with hematoxylin. Sections were analyzed with a Zeiss Axioskop
40 microscope and photographed with a Progress camera.
Mutation Analysis
Specimens, including frozen peripheral-blood cells, EBV-trans-
formed lymphoblast cell lines, and DNA samples, were collected
from patients after their parents provided informed consent. The
studywas approved by theNational Research Council. TNFRSF11A
gene (transcript ID number NM_003839) analysis was performed
by PCR ampliﬁcation with the primers reported in Table S1 (avail-
able online). All of the reactions were performed in 25 ml of ﬁnal
volumewith 0.4UTaq polymerase, 1.5mMMgCl2, 300 mMdNTPs,
10pmolof eacholigonucleotideprimer, and20ngofpuriﬁedgeno-
mic DNA. The thermocycling conditions used for ampliﬁcationconsisted of an initial denaturation step at 94C for 3min, followed
by 34 cycles of denaturation at 94C for 30 s and annealing at 60C
for 30 s and 72C for 30 s. The ampliﬁcation of exons 1 and 11 was
performed with the PCRx Enhancer System (Invitrogen). Auto-
mated sequencing was performed directly on the PCR products
puriﬁed from the gel.
Western-Blot Analysis of RANK Signaling
M-CSF-dependent peripheral-blood monocytes from Pt. 1A or
a healthy volunteer were cultured in 12-well tissue-culture plates
(2 3 105 cells/well) in a-MEM þ 10% fetal-calf serum þ 10 ng/ml
recombinant human M-CSF (R&D Systems). The cells were
starved of serum and M-CSF for 2 hr and then treated with 100
ng/ml recombinant human RANKL or 10 ng/ml TNFa (Peprotech)
for 10 or 15 min. Cells were then lysed in 50 ml buffer containing
10 mM potassium phosphate pH 7.4, 137 mM NaCl, 0.1% (w/v)
SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton X-100,
1mM EDTA, and protease and phosphatase inhibitors. Lysates
were cleared and assayed for protein with the use of the BCA assay
(Pierce). Fifty micrograms of protein from each sample were then
resolved by SDS-PAGE on 12% polyacrylamide-SDS gels followed
by transfer onto PVDF membranes and simultaneous hybridiza-
tion with anti-phospho p38 and total p38 antibodies or with
anti-phospho ERK1/2 and total ERK1/2 antibodies (Cell Signal-
ing). Bands were detected on a Li-Cor Odyssey imager after the
blots were incubated with Alexaﬂuor680- and IRDye800-conju-
gated secondary antibodies (Molecular Probes and Rockland
Immunochemicals, respectively).
Flow-Cytometry Analysis
Thepercentage of Tcells, B cells, andmyeloid cells in the peripheral
blood was assessed by the use of ﬂow cytometry. Fresh peripheral-
blood cells (23 105 cells), erythrocyte-depleted, were preincubated
for 15 min at RT with mouse serum and stained for 20 min at 4C
with the following mouse anti-human monoclonal antibodies,
fromBDPharMingenorCaltagLaboratories, either FITC, PE, perCp
or APC/conjugated: anti-CD3, anti-CD4, anti-CD8, anti-CD14,
anti-CD19, anti-CD20, anti-CD21, anti-CD27, anti-CD38, anti-
CD45RO, anti-CD80, anti-CD86, anti-CCR7, anti-IgD. After wash-
ing, cells were acquired on a FACScalibur ﬂow cytometer and
analyzed with FlowJo (version 4.5.4; Treestar) and FCSexpress
(version 3.0) software.
Lymphocyte Proliferation
Peripheral-blood mononuclear cells (PBMCs) were puriﬁed from
peripheral blood by centrifuge separation on Lymphoprep (Ny-
comed Pharma AS) and suspended in RPMI 1640 containing
10% FBS, 1% penicillin/streptomycin, 4 mM glutamine. For T cell
proliferation, 105 cells per well were placed in a round-bottom
96-well plate in the presence of human PMA (40 ng/ml) and Ion-
omycin (100 ng/ml) or with anti-CD3 antibodies (2 mg/ml) (BD
PharMingen) alone or combined with either anti-CD28 antibody
(5 mg/ml) (BD PharMingen) or IL-2 (100 U/ml) (Proleukin-Chiron).
T cell proliferation was analyzed after 72 hr of stimulation by the
use of a 16 hr pulse with 1 m Ci/well 3[H] thymidine (Amersham
Biosciences) followed by harvesting and counting via liquid
scintillation. All the experiments were performed in triplicate.
Monocyte-Derived Dendritic Cell Preparation
In brief, highly enriched monocytes were obtained from periph-
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centrifugation followed by CD14þ cell selection by immunomag-
netic beads (Miltenyi). Monocytes were cultured for 6 days at
106/ml in 6-well tissue-culture plates (Falcon; BD Biosciences) in
RPMI 1640 supplemented with 10% FCS, 50 ng/ml GM-CSF, and
20 ng/ml IL-4. Dendritic cell (DC) maturation was driven by
additional 24 hr culture in the presence of 200 ng/ml LPS.
Mixed-Leukocyte Reaction
5 3 104 immature or LPS-stimulated DCs were added to 5 3 105
CD45RAþ-enriched allogeneic T cells in 96-well plates. Each anal-
ysis was performed in triplicate. Cell proliferation was analyzed at
day 4 of stimulation by a 16 hr pulse with 1 m Ci/well 3[H] thymi-
dine (Amersham Biosciences) followed by harvesting and count-
ing by liquid scintillation.
Results
Clinical Evaluation of Patients
Here, we report eight patients from seven unrelated fami-
lies, found to have mutations in TNFRSF11A.
Pt. 1A and Pt. 1B were two siblings of Turkish consan-
guineous parents (Figure 1A, Family 1). The elder (Pt. 1A)
was ﬁrst hospitalized at 2.5 years of age with progressive
visual loss, nystagmus, and recurrent pneumonia. Physical
examination revealed an enlarged liver and spleen and in-
creased head circumference (>98th percentile). A CT scan
of the head showed enlarged lateral ventricles and severe
narrowing of the optic foramina. A blood count revealed
moderate anemia and thrombocytopenia. Immunological
investigation showed hypogammaglobulinemia and lack
of antibody response to tetanus antigen (0.005 IU/ml).
Peripheral-blood T and B cell absolute counts were normal
(data not shown). The patient was started on regular intra-
venous immunoglobulin infusions (IVIG) (400 mg/kg,
every 3 weeks). Prednisolone (5 mg/m2/day) and calcitriol
(0.5 mg/day) were given for 6 months. HSCT was not per-
formed due to lack of an HLA-matched donor. Bone hyper-
trophy in the nasal cavity caused a protracted suffocation
episode at the age of 5 years, which required tracheostomy.
However, irreversible CNS damage ensued, leading to a
permanent vegetative state.
Her brother, Pt. 1B, was diagnosed with osteopetrosis at
4 months. He had severe visual impairment, nystagmus,
hypotonia, and motor and mental retardation. Neither
fractures nor bone-marrow failure was observed. VEP and
BERA revealed slow stimuli transmission in anterior visual
pathways and bilateral peripheral and bulbopontine audi-
tory pathways, respectively. In addition, he suffered from
recurrent respiratory infections. X-rays documented a gen-
eralized increase in density consistent with the diagnosis
of osteopetrosis (Figure 2A, left). Hypogammaglobuline-
mia was diagnosed, and treatment with IVIG was given,
albeit irregularly. The child died of pneumonia at the age
of 3 years.
Pt. 2, of Argentinean origin, has previously been de-
scribed13 (Figure 1A, Family 2). At 45 days of age, abnormal
eye movements were noticed. Increased bone density was66 The American Journal of Human Genetics 83, 64–76, July 2008documented at 3.5 months, and a diagnosis of osteopetro-
sis was established. At that time, moderate anemia (Hb 9.1
g/dL) was present. Bone-marrow biopsy showed decreased
cellularity, with reduced hematopoiesis and lack of osteo-
clasts. Brain MRI was normal and the patient had good de-
velopment of social skills, but gross motor milestones were
delayed. The infant received a 4/6 HLA antigen-matched
unrelated-cord-blood transplant at 8 months of age, with
a preparative regimen consisting of busulfan (8 mg/kg),
ﬂudarabine (175 mg/m2), antithymocyte globulin (ATG
horse; 150 mg/kg) and total-lymphocyte irradiation (TLI
500 cGy). Initial engraftment was followed by loss of the
graft by day þ100. The patient died of respiratory arrest
at less than one year after transplant. Post mortem exami-
nation was not performed.
Pt. 3 was the third child of unrelated Caucasian parents
(Figure 1A, Family 3). He presented during the ﬁrst week of
life with hypocalcemic seizures, which responded to cal-
cium and vitamin D. He was hospitalized again, at 6 weeks
and at 2 months of age, with respiratory infections. A diag-
nosis of ARO was made at 3 months, when he was noticed
to have no eye contact and was not smiling. He had bilat-
eral optic-nerve atrophy; visual evoked responses were
delayed and abnormal, consistent withmarked optic nerve
compression. He was pale, with mild hepatosplenomegaly,
and was not gaining weight normally. Skeletal radiography
revealed multiple rib fractures and dense bones (Figure 2A,
right). He suffered several episodes of cardiac/respiratory
arrest due to hypocalcemia and respiratory infections and
was started on interferon-gamma treatment. At 5 months
of age, a bone biopsy (Figure 2E) showed increase of
bony and cartilaginous trabeculae, narrowing of marrow
space, and very few osteoclasts. Immunological investiga-
tion revealed hypogammaglobulinaemia and lack of anti-
body response to tetanus toxoid (Table 1), with normal pe-
ripheral blood T and B lymphocyte absolute numbers (data
not shown). HSCTwas performed from a 7/8 HLA-antigen-
matched unrelated donor at 7 months, after myeloablative
conditioning with busulfan (16mg/kg) and cyclophospha-
mide (200 mg/kg) with Campath 1G from day 4 to day
þ4. A total dose of 1.5 3 109/kg bone-marrow nucleated
cells were infused. Cyclosporin A was used for prophylaxis
of graft-versus-host disease (GvHD). At the time of very
early signs of engraftment, on day þ15 he developed
severe hepatic veno-occlusive disease (VOD), followed by
pneumonitis on day þ19, progressing to multi-organ sys-
tem failure and death on day þ22. Autopsy conﬁrmed
acute respiratory distress syndrome (ARDS) and severe liver
VOD as causes of death, as well as atrophy of optic and
olfactory nerves due to bone compression and engraft-
ment with evidence of hemopoiesis and osteoclast activity.
Pt. 4 is the ﬁrst child born to ﬁrst-cousin Pakistani parents
(Figure 1A, Family 4). At 7 days, he developedhypocalcemic
seizures. Poor visual ﬁxation and roving nystagmus were
noticed at 6.5 months, and optic-nerve atrophy was dem-
onstrated with an MRI scan. A hand radiograph showed
alternating bands of radio density and lucency at the
Figure 1. Pedigree of the Affected Patients and Mutation Analysis
(A) Pedigrees of the seven analyzed families. Black circles or squares in the pedigrees indicate affected members with both mutated
alleles. Half-black circles or squares indicate heterozygous members with only one mutated allele. White symbols indicate members
not analyzed, except those with asterisks in Family 7, which have been analyzed and are normal. Below each pedigree, the amino
acid change(s) is indicated.
(B) Chromatograms of the seven mutations in the TNFRSF11A gene are indicated.The American Journal of Human Genetics 83, 64–76, July 2008 67
metaphyses and increased bone density of the diaphyses,
thus conﬁrming the diagnosis of osteopetrosis. The liver
was palpable 2 cm below the costal margin, but no signiﬁ-
cant hematological abnormalities were present. HSCT was
performed, with the patient’s HLA-identical mother as
donor. Full engraftment was associated with resolution of
radiological features of osteopetrosis. However, feeding
difﬁculties, developmental delay, and lack of vision have
persisted. At two years of age, the patient shows a lack of
speech development.
Pt. 5 is the second child of a consanguineous Caucasian
couple (Figure 1A, Family 5). He presented at 3 days of life
with afebrile seizures, which required prolonged treatment
with phenobarbital. A CT scan of the brain showed multi-
ple hematomas. At 2 months of age, the infant was noticed
to have no eye contact. Visual evoked responses were de-
layed and abnormal. Skeleton X-ray examination was
compatible with osteopetrosis. The patient was referred
for HSCT at 8 months of age. At that time, severe develop-
mental delay, growth failure (weight and length < 3rd per-
centile), and nystagmus were present. There were no signs
of liver or spleen enlargement. A bone-marrow biopsy
(Figures 2B–2D) showed thickened trabecular bone with
Figure 2. Chest X-Rays and Bone Biop-
sies of Some Patients
(A) Bone thickening of vertebrae and ribs
is evident, revealing classical osteope-
trotic phenotype in Pt. 1B and Pt. 3. Panels
B–D show bone biopsies from Pt. 5, panel E
from Pt. 3.
(B) Toluidine-blue staining: dark purple in-
dicates cartilage, blue indicates bone.
(C) Hematoxylin-eosin staining: abundant
hematopoietic cells in the scarce marrow
spaces; cartilage is shown in gray and
bone in pink. There are neither multinucle-
ated cells nor active osteoblasts.
(D) TRAcP staining, counterstained with
hematoxylin. No TRAcP positive cells are
present; the inset shows a control section
with a TRAcP-positive osteoclast for com-
parison.
(E) Section of bone from Pt. 3 stained with
hematoxylin and eosin, illustrating abun-
dance of trabecular bone (pink) and carti-
lage (gray), absence of multinucleated
cells, and absence of active bone forma-
tion.
Scale bar represents 50 mm in panels B–E.
Scale bar in panel D represents 10 mm.
reduced lacunae and presence of nor-
mal hematopoietic lines. No signs of
osteoclast activity were documented.
The infant developed recurrent sei-
zures, with myoclonic twitches and
irregular theta waves admixed with
high-frequency activity at EEG tracing. Immunological
evaluation revealed normal serum immunoglobulins (Ta-
ble 1). HSCT was performed from an HLA-identical sibling
at 1 year of age, after myeloablative conditioning with bu-
sulfan (20 mg/kg), thiotepa (5 mg/kg) and cyclophospha-
mide (200 mg/kg). A total of 0.35 3 109/kg bone-marrow
nucleated cells, containing 4.9 3 106/kg CD34þ cells,
were infused. Cyclosporin A was used for prophylaxis of
GvHD. Full donor engraftment was achieved. At 3 years af-
ter transplantation, the patient has normal hematopoiesis,
with correction of radiological signs of osteopetrosis. Pro-
gressive improvement of EEG tracing has been recorded,
allowing for gradual tapering of anticonvulsants.
Pt. 6 was born from consanguineous Pakistani parents
(Figure 1A, Family 6); there appeared to be no relationship
between this family and the family of Pt. 4. She was diag-
nosed at 9 months of age, when she presented with hydro-
cephalus. She was also Bilevel Positive Airway Pressure (Bi-
PAP)-dependent. Routine X-rays done at that time showed
features of ARO and a fracture of the left femur. Vision was
normal at presentation, but progressive visual loss devel-
oped, and focal narrowing of optic nerves was revealed
by MRI. No hepatosplenomegaly was reported. EMG68 The American Journal of Human Genetics 83, 64–76, July 2008
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ve at 4.5 years alive at 2 years alive at
5 yearsTable 1. Clinical and Laboratory Features
Clinical Dataa Pt. 1A Pt. 1B Pt. 2 Pt. 3 Pt. 4 Pt
Age at onset/diagnosis 3 months/2.5 years 1 month/4 months 2 months/3.5 months 1 week/3 months 1 week/6 months 1 w
Bone biopsy (pre-HSCTc) nd nd few/no osteoclasts,
significant reduction
of medullary space
few/no osteoclasts,
significant reduction
of medullary space
nd few
sig
of
Bone fractures no no no multiple ribs no no
Neurological defects severe visual impairment,
nystagmus, enlarged
lateral ventricles,
severe motor and
mental retardation
severe visual impairment,
nystagmus, hypotonia,
severe motor and
mental retardation
visual impairment,
nystagmus, delayed
gross motor milestones
visual impairment,
mild hearing loss,
hypocalcemic spasms,
mild developmental
delay
visual impairment,
neurodevelopmental
delay, hypocalcemic
seizures
vis
ny
de
Hepatospleno-megaly yes no no yes mild hepatomegaly no
Other features recurrent pneumonia recurrent upper respiratory
tract infections
none respiratory infections
growth failure
none gro
Hbd (g/dl) 10.0 8.7 9.1 10.5 10.0 10
Plte (3 109/L) 150 191 170 346 223 33
WBCf (3 109/L) 15.2 11.9 33.5 9.4 9.8 11
Neutrophils (% of WBCf) 42 37 nd 14 25 41
Lymphocytes (% of WBCf) 56 57 nd 73 60 47
Monocytes (% of WBCf) 2 6 nd 10 5 nd
Immunoglobulin G (mg/dl) 435 (604–1941) 354 (605–1430) nd 144 (230–850) nd 50
Immunoglobulin M (mg/dl) 45.1 (71–235) 18 (66–228) nd 19 (19–86) nd 66
Immunoglobulin A (mg/dl) 22.5 (26–296) 29 (30–107) nd 33 (10–50) nd 76
Tetanus vaccination (IU/ml) 0.005 nd < 0.08 (> 0.1) nd nd
Age at HSCTc not performed not performed 8 months 7 months 6 months 1 y
HSCg origin umbilical cord bone marrow bone marrow bo
Donor blood unrelated unrelated HLA-id parent HL
T cell depletion (TCD) - - no TCD no TCD no TCD no
Engraftment (% donor
chimerism)
- - graft loss day þ100 osteoclast activity
(post mortem)
100% 10
blo
Bone remodeling - - n/a n/a yes (X-ray) ye
Outcome alive at 7 years died at 3 years died < 1 yr
post-HSCT
died day þ22
post-HSCT
alive at 5 years ali
nd: not done; n/a: not assessed.
Normal values for 1-year-old children: WBC ¼ 6–17.5; Hb ¼ 10.5–12.0; Plt ¼ 150–400.
a All of the laboratory data reported refer to the time of the first diagnosis.
b BiPAP: Bilevel Positive Airway Pressure.
c HSCT: Haematopoietic Stem Cell Transplantation.
d Hb: Hemoglobin.
e Plt: Platelets.
f WBC: White Blood Cells.
g HSC: Haematopoietic Stem Cells.
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revealed chronic denervation and reinnervation in both
bulbar and limb musculature. Foramen magnum decom-
pression was performed as a result of the restriction of
posterior fossa and foramen magnum, with consequent
cerebellar peduncles towering. The patient has not yet
been transplanted and is alive at 2 years of age.
Pt. 7 is the ﬁrst child of consanguineous Turkish parents
(Figure 1A, Family 7). When he was 2 months old, abnor-
mal eye movement was observed by his family. He had
a bone fracture at 8 months. X-ray suggested a diagnosis
of ARO, and the patient was referred to Hacettepe Chil-
dren’s Hospital. At admission, he was 9 months old, with
a weight of 7 kg (3rd–10th percentile) and a height of 68
cm (25th percentile) and mild anemia (Hb: 8.9 g/dL). Light
reﬂex was poor, and mild hepatosplenomegaly was de-
tected. Exophtalmus was prominent. He has no recurrent
infection history and is alive at 5 years of age without
transplant.
Bone Biopsies
Bone-biopsy specimens were available in three patients. As
previously described,13 extensive trabecular structures,
with retention of large areas of cartilage, complete absence
of multinucleated cells, and lack of osteoclastic resorption,
were present in Pt. 2. Similar ﬁndings were observed in
bone biopsies from Pt. 3 and Pt. 5 (Figures 2B–2E). Histo-
chemical staining for TRAcP was negative and excluded
possible presence of small, mononuclear osteoclasts in
the bone biopsy from Pt. 5 (Figure 2D).
Genetic Findings
Among 230 patients with a clinical diagnosis of ARO re-
ferred to our institution for genetic investigation, about
28% lack mutations in genes known to cause ARO.
Here, we report the identiﬁcation of mutations in the
TNFRSF11A gene in seven unrelated families (Figure 1B
and Figure 3).
In Family 1, both siblings carried a homozygous transi-
tion, c.508A / G, causing a p.Arg170Gly amino acid
change in the extracellular domain of RANK, and their par-
ents and several relatives were heterozygous for the nucle-
otide substitution.
Pt. 2 was a compound heterozygote for two transitions,
c.385C/ T and c.523T/ C, leading to predicted amino
acid changes, p.Arg129Cys and c.523T/ C, respectively,
both in the extracellular domain. The p.Cys175Arg muta-
tion also lies at an exon-intron boundary.
Pt. 3 shared with Pt. 2 the c.523T/ C change on one
allele, whereas on the other he had a c.730G/ T transver-
sion, causing a p.Ala244Ser amino acid substitution in the
intracellular domain.
Pt. 4 and Pt. 6 were homozygous for a c.157G / C
transversion, causing a p.Gly53Arg amino acid change
in the extracellular domain. Both consanguineous parents
from both families were heterozygous for the same
mutation.70 The American Journal of Human Genetics 83, 64–76, July 2008Pt. 5 was homozygous for a c.1301G / A mutation,
causing a stop at codon 434 (p.Trp434X) in the intracellu-
lar domain.
Pt. 7 was homozygous for a c.838G/ T mutation, caus-
ing a stop at codon 280 (p.Gly280X) in the intracellular
domain. Both consanguineous parents were heterozygous
for the mutation. DNA from 18 additional family mem-
bers, of which 12 were heterozygous, was analyzed.
None of the missense mutations were found in more
than 100 chromosomes from healthy unrelated individ-
uals from the same geographical areas. This translates to
an 80% power of detecting an SNP with 2% frequency.14
Sequence alignment of human RANK protein with that
of other mammals and chicken showed that the affected
residues G53, R129, C175, and A244 are highly conserved
throughout evolution, although R170 displays a lower
degree of conservation (Figure 3).
Osteoclast Differentiation and Function in Patients
from Families 1, 6, and 7
We analyzed the ability of osteoclasts to differentiate
in vitro from monocytes isolated from nontransplanted
patients (Pt. 1A, Pt. 1B, Pt. 6, Pt. 7), as compared to appro-
priate controls. Monocytes were induced to differentiate
toward the osteoclast lineage by culturing with M-CSF
and RANKL.6,12 Whereas multinucleated, VNR-positive
osteoclasts formed readily in cultures from the (unrelated)
control, very few osteoclasts formed from either Pt. 1A or
Pt. 1B under these conditions (Figure 4A; osteoclast num-
bers: 2.85 1.7 for Pt. 1A, compared to 61.85 23 for unre-
lated control; means 5 SD of four replicates). Although
some VNR-positive cells could be detected, these were
mostly mononuclear or binuclear, similar to control cul-
tures with M-CSF alone (data not shown). In cultures of
PBMCs from Pt. 6 (data not shown) and Pt. 7 (Figure 4B),
osteoclast formation was equally absent, with only small
mononuclear VNR-positive cells formed in numbers simi-
lar to those seen in cultures with M-CSF alone, whereas
in (parent) control cultures, large multinucleated osteo-
clasts were formed (osteoclast numbers: 4 5 1.1 for Pt. 6,
compared to 324 5 45 for parent control, and 1.5 5 0.6
for Pt. 7, compared to 127.3 5 28 for unrelated control;
means 5 SD of at least four replicates). Moreover, when
cultured on dentine, osteoclasts from the control of Pt.
1A polarized their cytoskeleton into a characteristic F-actin
ring and resorbed large pits in the dentine, whereas none
of the cells in the patient cultures formed actin rings or
showed any evidence of resorptive activity (Figure 4C
and Figure S1). Also, mononuclear cells in patient cultures
were predominantly spindle-shaped, indicative of defects
in the early stages of differentiation toward the osteoclast
phenotype (Figure 4 and Figure S1).
Stimulation through the RANKL-RANK axis activates
downstream signaling pathways involving phosphoryla-
tion of p38.15 When cultured monocytes were exposed
to RANKL, a marked increase in phosphorylated p38 and
ERK1/2 was detected in lysates from control cells but not
Figure 3. Mutations in Relation to the RANK Protein Structure
(A) Schematic representation of the RANK protein and the mutations found in our patients. The intracellular (In) and extracellular (Out)
sides of the membrane (depicted in blue) are represented. Letters and numbers inside the circles indicate the mutated residues. The Y141
inside the square (blue) is a polymorphism not previously described.
(B) Alignment of RANK protein sequences from several species in the regions covering the identified mutations. The mutated residues
(red) are indicated above the sequences. The corresponding residues in the individual sequences are also in red. The graphical view
of domain structure was obtained by ProtoNet (automatic hierarchical classification of protein sequences).fromPt. 1A cells. The speciﬁcity of the defect for RANKL sig-
nalingwas conﬁrmedby the fact that TNFa inducednormal
p38 and ERK1/2 phosphorylation in both control and pa-
tient cells (Figure 4D). Sufﬁcient cells from other patients
for examination of abnormalities in RANK signaling were
unavailable.
Immunological Investigations
Serum immunoglobulin levels were assessed in four out of
eight patients and were reduced in three of them (Pt. 1A,
Pt. 1B, and Pt. 3; see Table 1). In addition, two of thesepatients (Pt. 1A and Pt. 3) failed to produce antibodies after
a full course of tetanus toxoid vaccination (Table 1).
In Tnfrsf11a/ mutant mice, a developmental defect in
the B cell lineage, resulting in amarked reduction ofmature
B cells in the periphery, has been described.8 Hence, a de-
tailed immunological analysis was carried out with the
peripheral blood obtained from Pt. 1A and Pt. 1B. In partic-
ular, we analyzed the following B cell subsets: naive
(IgDþCD27), memory (IgDþCD27þ), and switched-mem-
ory (IgDCD27þ). Although both patients (tested at 6 and
3 years of age, respectively) had normal proportions ofThe American Journal of Human Genetics 83, 64–76, July 2008 71
Figure 4. Mutations in TNFRSF11A Pre-
vent p38 and ERK1/2 Signaling and
Inhibit the Formation of Osteoclasts
(A) Osteoclasts were generated from PBMCs
of nontransplanted patients 1A and 1B and
one unrelated control (CONTROL), in con-
current cultures. One-micrometer confocal
images of cells were cultured on glass cov-
erslips. Osteoclasts were immunostained
for avb3 (green); acidic vesicles were la-
beled prior to fixation with lysotracker
(red); nuclei were stained with TO-PRO-3
iodide (blue). Multinucleated, avb3-posi-
tive osteoclasts formed readily in control
cultures, whereas in the patient cultures,
avb3-positive cells were much scarcer
and were not multinucleated.
(B) Osteoclasts were generated from PBMCs
from nontransplanted Pt. 7 and one of his
parents (CONTROL) on tissue-culture plas-
tic. Images were taken with a nonconfocal
fluorescent microscope. Osteoclasts are
stained for avb3 (green), and nuclei are
stained with DAPI (pseudocolored red).
Clearly, cultures from Pt. 7 do not demon-
strate any multinucleated VNR-positive
cells, whereas these are abundant in the
parent-control culture.
(C) Confocal images (1 mm optical slices) of
cultures on dentine discs. Cultures were
immunostained for avb3 (green), then
counterstained with TRITC-phalloidin to
visualize osteoclast F-actin (red). The den-
tine surface was labeled with FL-ALN
(blue); dark areas correspond to resorption
pits (absence of FL-ALN) and are indicated
by asterisks. Actively resorbing osteoclasts
formed in the control cultures but not in
the cultures from either patient.
Scale bars in panels A and C represent 10mm.
Scale bar in panel B represents 50 mm.
(D) M-CSF-dependent macrophages from
Pt. 1A or from a healthy control (CONTROL)
were treated for 10 min with RANKL or for
15 min with TNFa. Cell lysates were then
analyzed for the presence of phosphorylated and total forms of p38 and ERK1/2. There is an increase in phosphorylation of p38 and
ERK1/2 in response to RANKL in the control cells but not in the patient cells, whereas both patient and control respond to TNF by
increased phosphorylation of p38 and ERK1/2.circulating CD19þ B cells, IgDCD27þ B cells were mark-
edly reduced (Figure 5). These cells were present in both
TCIRG1- and OSTM1-deﬁcient patients but absent (as ex-
pected) in a HyperIgM patient with a CD40 defect (MIM
606843). Interestingly, a TNFSF11-dependent ARO patient
had a normal percentage of these cells when tested at the
age of 6 years. Phenotypical and functional analysis of T
lymphocytes did not reveal any major abnormalities (data
not shown). Because osteoclasts originate from a precursor
common to DC lineage, we investigated the in vitro re-
sponse to IL-4 and GM-CSF of CD14þ monocytes puriﬁed
from Pt. 1A and Pt. 1B. These cells were able to differentiate72 The American Journal of Human Genetics 83, 64–76, July 2008into immature DCs, and upon LPS stimulation, they
normally upregulated activation markers (CD80, CD86).
Moreover, when immature and mature DCs were tested in
MLRassays for their priming ability toward allogeneic naive
T cells, no defects were observed (Figure 6 and Figure 7).
Overall, these data suggest no defects in dendritic function.
Discussion
Mutations in the signal peptide of RANK have been associ-
ated with unusual skeletal phenotypes, including familial
Figure 5. Cytofluorimetric Analysis of
Naive and Memory B Cells in Osteo-
clast-Poor, TNFRSF11A-Dependent ARO
Patients
FACS analysis of a pediatric normal donor
(7 years), a cord-blood sample, a Hyper-
IgM-3 patient with CD40 defect, Pt. 1A
(6 years), Pt. 1B (3 years), a TNFSF11-de-
pendent ARO patient (6 years), and an
OSTM1-dependent osteoclast-rich ARO
patient (2 years). Mature B cells were
then analyzed for IgD and CD27 surface
expression.expansile osteolysis (FEO [MIM 174810]), expansile skele-
tal hyperphosphatasia, and early-onset Paget disease
(PDB [MIM 602080]).16–18 Here, we report the ﬁrst exam-
ple, to our knowledge, of mutations in the human
TNFRSF11A gene causing a defect in osteoclast formation
leading to the clinical ﬁndings of osteopetrosis. In our se-
ries of seven unrelated families, there were ﬁve missense
mutations, of which four caused amino acid substitutions
in the extracellular domain, one caused amino acid substi-
tutions in the intracellular domain, and two caused stop
mutations within the intracellular domain. It is likely
that the mutations in the extracellular domain affect the
interaction of RANK with RANKL. The complete lack of
p38 (MIM 600289) and ERK1/2 signaling through RANK
seen in the p.Arg170Glymutation (Family 1) strongly indi-
cates that the receptor is dysfunctional. The p.Gly280X
and p.Trp434X truncating mutations in the intracellular
domain cause the loss of a region (535IVVY538 in mouse,
AA 547–550 in humans) known to be essential for commit-
ment of macrophages to the osteoclast lineage and for
ligand-independent oligomerization of RANK,19,20 as well
as the loss of NFkB-activating motifs required for osteoclast
formation.21 However, the effect of the p.Ala244Ser muta-
tion is less clear, because this region of RANK can be
deleted without affecting osteoclast formation.20 Further
studies are required to fully understand the effect of each
of these mutations in RANK on receptor oligomerization
and downstream signaling pathways. Of note, Pt. 1A, Pt.
1B, and Pt. 3 showed immunoglobulin deﬁciency and Pt.
1A and Pt. 3 also failed to produce antibodies to tetanus
toxoid. Analysis of PBMC from both patients from Family
1 suggested that the TNFRSF11A mutation is associated
with a partial defect in peripheral B cell maturation, given
that a reduced number of memory switched cells was
found in these patients but not in osteoclast-rich ARO
patients. Overall, the defects identiﬁed in these patients
are compatible with a diagnosis of Common Variable
Immune Deﬁciency (CVID). However, normal serum im-munoglobulin levels were reported in Pt. 5, suggesting
some variability of the immunological phenotype.
The prevalence of osteoclast-poor osteopetrosis is not
easily determined because bone biopsies are rarely per-
formed in ARO patients. In our series of 230 families, we
detected six families bearing TNFSF11 mutations (ref. 6
and unpublished results) and seven families with
TNFRSF11A abnormalities (this paper). In addition, we
have ﬁve cases of bone-biopsy-documented osteoclast-
poor ARO patients in whom no mutation was found in
these genes. This suggests that osteoclast-poor forms con-
tribute to less than 10% of ARO cases and that for about
30% of these, the gene is still unknown.
The exact reasons for the defect in immunoglobulin (Ig)
production shown in three patients from two different
families are not completely clear. To our knowledge, no
data on serum Ig isotype levels was reported for the
Tnfrsf11a/ mice. We were able to document impairment
in memory B cell populations in the two analyzed
brothers. One hypothesis is that RANK could contribute,
together with other receptors of the TNFR family, to the
process of Ig switch and antibody maturation. Alterna-
tively, the process of antibody response to antigens in
thesemice could be altered by their defect in the formation
of secondary lymphoid tissues. Unfortunately, we were un-
able to investigate the lymph-node status in our patients
because no imaging studies were performed during life
and no autopsy was performed at death.
Tnfrsf11a deﬁciency in mice has also been associated
with severe abnormalities in thymic epithelial cells and
impaired negative selection, with severe autoimmune
manifestations.22 Therefore, these abnormalities could
not be corrected by HSCT. However, none of our patients
developed autoimmunity before or after HSCT, possibly
indicating a less-critical role for both RANKL and RANK
in immune homeostasis in humans.
In the last few years, the molecular dissection of ARO
heterogeneity has allowed us to identify at least fourThe American Journal of Human Genetics 83, 64–76, July 2008 73
Figure 6. In Vitro Differentiation of
Dendritic Cells
(A) DC phenotypes of healthy donor, Pt.
1A, and Pt. 1B were assessed by cytofluori-
metric analysis after 6 days of culture of
CD14þ-enriched monocytes in the presence
of GM-CSF and IL-4.
(B) DC maturation in response to 24 hr of
LPS exposure was confirmed by the expres-
sion of maturation markers (CD80 and
CD86). Black-filled histograms represent
expression of CD80 and CD86 on non-LPS-
stimulated cells, whereas gray-lined empty
histograms represent expression on LPS-
stimulated cells.genotypes in the osteoclast-rich form and two subsets in
the osteoclast-poor form. The genetic defect could not be
characterized in about 25% of patients in our series. How-
ever, the molecular defects identiﬁed thus far are already of
clear clinical and prognostic relevance.23 Patients with
TNFRSF11A-deﬁcient ARO share with the TCIRG1-depen-
dent ARO patients the classical osteopetrotic phenotype
(OPTB1 [MIM 259700]), including secondary neurological
symptoms, and both can be cured with HSCT. However,
the clinical course of both TNFRSF11A-deﬁcient and
TCIRG1-deﬁcient ARO clearly differs fromwhat is observed
in AROs caused by mutations in OSTM1 (MIM 607649)
and, to some extent, ClCN7 (MIM 602727). Patients with
the latter AROs are characterized by rapid and severe pri-
mary central nervous system involvement that cannot be
rescued by HSCT; thus, additional neurological investiga-
tions should be performed prior to the offer of transplanta-
tions. The TNFRSF11A-dependent form of ARO also differs74 The American Journal of Human Genetics 83, 64–76, July 2008from the osteoclast-poor TNFSF11-dependent form of
ARO, which cannot be rescued with HSCT but which is
potentially responsive to exogenous-RANKL administra-
tion. Although RANK-mediated signaling plays a role in
B cell maturation, no obvious immunological defect was
identiﬁed in the TNFSF11-dependent ARO patients that
we previously reported.6 On the contrary, defective immu-
noglobulin production in three patients with TNFRSF11A-
defective ARO, together with the documented impairment
of B cell maturation in the two patients tested at the cellu-
lar level, suggests that, at variance with mice, mutations in
the receptor or its ligand have different effects on the de-
velopment of the immune system in humans. Additional
studies are needed in order to clarify whether other,
TNFSF11-independent, signaling pathways are responsible
for this difference. Overall, these results highlight the
clinical importance of the molecular diagnosis of genetic
diseases of bone.Figure 7. Mixed Lymphocyte Reaction
53 103 CD1aþCD14 cells, immature DCs, and mature DCs were
cultured with 53 104 CD4þCD45RAþ naive allogenic T lympho-
cytes, purified from healthy-donor peripheral blood. Prolifera-
tive responses were assessed by 3[H] thymidine incorporation
after 72 hr of coculture, after a 16 hr pulse with 1 m Ci/well
3[H] thymidine. Vertical bars indicate standard errors calcu-
lated over three replicates.
Supplemental Data
One table and one ﬁgure are available at http://www.ajhg.org/.
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